二至丸及其组成药味保肝药理作用研究进展

二至丸由女贞子和墨旱莲两味中药组成,这两味药及其组方均有不同程度的保肝作用。二至丸中含有多种保肝有效成分,主要有三萜类、环烯醚萜类、苯乙醇-苷类、香豆素醚类等,它们能对抗多种化学性肝损伤、抗缺血再灌注性肝损伤以及抗肝纤维化等,其保肝作用机制包括抗氧化应激、抗炎、抑制肝星状细胞增殖和活化、促进肝星状细胞凋亡以及影响肝细胞代谢过程等。总结二至丸及其组成药味女贞子和墨旱莲的保肝作用,探讨其保肝作用机制,以期为进一步研究二至丸药效物质基础提供参考。...

Full description

Saved in:
Bibliographic Details
Published in药学实践杂志 Vol. 34; no. 4; pp. 289 - 291
Main Author 胡冬梅 陈小玲 陆杨 房敏峰 王婧雯 文爱东
Format Journal Article
LanguageChinese
Published 第四军医大学附属西京医院药剂科，陕西 西安 710032 2016
西北大学生命科学学院，陕西西安710069%空军94647部队63分队,福建福州,350026%第四军医大学附属西京医院药剂科,陕西 西安,710032%西北大学生命科学学院,陕西西安,710069
Subjects
二至丸
保肝作用
墨旱莲
女贞子
肝损伤
墨旱莲
Herba Ecliptae
女贞子
Ligustri Lucidi Fructus
保肝作用
hepatoprotective effect
二至丸
Erzhiwan
hepatic injury
肝损伤
Online AccessGet full text
ISSN1006-0111
DOI10.3969/j.issn.1006-0111.2016.04.001

Cover

More Information
Summary:二至丸由女贞子和墨旱莲两味中药组成,这两味药及其组方均有不同程度的保肝作用。二至丸中含有多种保肝有效成分,主要有三萜类、环烯醚萜类、苯乙醇-苷类、香豆素醚类等,它们能对抗多种化学性肝损伤、抗缺血再灌注性肝损伤以及抗肝纤维化等,其保肝作用机制包括抗氧化应激、抗炎、抑制肝星状细胞增殖和活化、促进肝星状细胞凋亡以及影响肝细胞代谢过程等。总结二至丸及其组成药味女贞子和墨旱莲的保肝作用,探讨其保肝作用机制,以期为进一步研究二至丸药效物质基础提供参考。
Bibliography:HU Dongmei , CHEN Xiaoling , LU Yang , FANG Minfeng , WANG Jingwen , WEN Aidong （1. Department of Pharma- cy, Xijing Hospital, Fourth Military Medical University, Xi＇an 710032, China; 2. College of Life Science, Northwest Univer- sity, Xffan 710069, China; 3. No. 63 Troops,The Air Force of 94647, Fuzhou 350026, China）
31-1685/R
Erzhiwan;Ligustri Lucidi Fructus ; Herba Ecliptae ; hepatic injury; hepatoprotective effect
Erzhiwan includes two components of Chinese herbal medicines--Ligustri Lucidi Fructus and Herba Eclip- tae. Ligustri Lucidi Fructus, Herba Ecliptae and their formulation have various hepatoprotective effects. There are many ac- tive ingredients in the formulation, such as triterpenes, iridoids, phenethyl alcohol-glucosides, coumarin ethers, etc. They can resist various chemistry-induced hepatic injury, ischemia reperfusion induced hepatic injury, and hepatic fibrosis. The mecha- nisms of hepatoprotective effect include anti-oxidative stress, anti-inflammatory, inhibition of hyperplasia and activati
ISSN:1006-0111
DOI:10.3969/j.issn.1006-0111.2016.04.001